Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Revenue of Belite Bio, Inc (BLTE)
Revenue in 2023 (TTM): $
According to Belite Bio, Inc's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Belite Bio, Inc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-399,000 | $-31,529,000 | $-31,623,000 | $-31,632,000 |
| 2022 | $ | $-198,000 | $-12,434,000 | $-12,648,000 | $-12,475,000 |
| 2021 | $ | $-30,000 | $-9,636,000 | $-9,666,000 | $-9,792,000 |
| 2020 | $ | $-17,000 | $-5,714,000 | $-5,752,000 | $-5,753,000 |